FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

GLENMARK Share Price Discussion

Glenmark Pharmaceuticals Ltd.
NSE: GLENMARK | BSE: 532296 | ISIN: INE935A01035 | Sector: Pharmaceuticals and health care

GLENMARK Rating

3.2/5 (13 Ratings)
GLENMARK Share Price *
321.55 +3.45 (1.08%)
* (quote may be delayed)
Find answers to all your questions on live GLENMARK message board: Is GLENMARK buy or sell? Should I buy GLENMARK shares? Why are GLENMARK shares falling? Should I invest in GLENMARK stock?

You can also check GLENMARK share price target recommended by brokerages.

GLENMARK Discussion Forum

@sifm • Reputation: -4,176
GLENMARK FEB20 FUT

Type
Buy
Instrument
GLENMARK FEB20 FUT
Entry Price
₹327
Price@Trade
₹326.55
Target Price
₹331
Stop Price
₹323
Valid Till
Feb 20, 2020 3:20 PM
Status
Exited before entry
Like
reply
Reply (1)
Latest replies
Ashish Tiwari @sifm
Feb 20 8:45 PM

Update
Exited before entry
Price @ Update
₹322.5
@sid-H16FVBj4V • Reputation: 239
GLENMARK FEB20 FUT

Type
Buy
Instrument
GLENMARK FEB20 FUT
Entry Price
₹326.3
Price@Trade
₹326.85
Target Price
₹327.3
Stop Price
₹325.8
Valid Till
Feb 20, 2020 3:20 PM
Margin
₹92,968.23 approx for 1400 Qty
Status
Stoploss Hit
Exit Price
₹325.8
Net P&L
-0.75% Loss
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 20 6:03 PM

Update
Trade Entered
Entry Price
₹326.3
TrackerBot @trackerbot
Feb 20 6:06 PM

Update
Stoploss Hit
Exit Price
₹325.8
@balaji3516 • Reputation: 13,760
GLENMARK

Type
Sell
Instrument
GLENMARK
Entry Price
₹322.5
Price@Trade
₹322.05
Target Price
₹31
Stop Price
₹324.2
Valid Till
Feb 20, 2020 3:20 PM
Margin
₹322.5 approx for 1 Qty
Status
Exited
Exit Price
₹323.4
Net P&L
-0.28% Loss
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 20 4:19 PM

Update
Trade Entered
Entry Price
₹322.5
Balaji  @balaji3516
Feb 20 5:38 PM

Update
Exited
Exit Price
₹323.4
Net P&L
-0.28% Loss
@nikuj • Reputation: 0
Q. What is the view on Glenmark
Like
reply
Reply (2)
Latest replies

May Test 300-295 & Reverse 👍
Balaji  @balaji3516
Feb 18 2:18 AM

Having support at 295-297 levels ..if it holds then upmove..but it is risky to enter now
@mrk-BkWUfpPbL • Reputation: 0

Is it going to fall or rise?
Like
reply
Reply
GLENMARK

Type
Sell
Instrument
GLENMARK
Entry Price
₹315.9
Price@Trade
₹315.9
Target Price
₹310
Stop Price
₹319
Valid Till
Feb 17, 2020 3:20 PM
Margin
₹315.9 approx for 1 Qty
Status
Exited
Exit Price
₹312.4
Net P&L
1.11% Profit
Like
reply
Reply (1)
Latest replies

Update
Exited
Exit Price
₹312.4
Net P&L
1.11% Profit
@Zerodhapartner • Reputation: 112

GLENMARK - chart - 604725

Like
reply
Reply
@alokbihani • Reputation: 176
Alok Bihani in GLENMARK
Amid the coronavirus Pharma industry is making ...

GLENMARK - chart - 604694
BANG BANG BANG !!! hits all target on long side.
Sorry for delay in update. Chart attached for refernce.
will post new levels ASAP. Dm me for further details if required.
Like
reply
Reply (2)
Latest replies
lost somewhere @lost
Feb 15 8:39 PM

Tell something about coal india stuck in there
Alok Bihani @alokbihani
Feb 16 1:12 AM

Will post my view with charts nd levels on Coal India tonight..pls chck Coal India forum
@newsbot • Reputation: 2,308
Glenmark Q3 net profit rises 64% to Rs 190.83 cr; to raise $400 mn
The company had posted a net profit of Rs 116.34 crore in the corresponding period of the previous financial year, Glenmark Pharmaceuticals said in a filing to the BSE.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Taking Stock | Supreme Court raps telcos for not paying up; Sensex falls below 50-DMA
The apex court's stance weighed on financial stocks also because of their exposure to the sector.
Moneycontrol
Like
reply
Reply

Reversal day for GLENMARK is Feb 17 based on Gann Astro method
Like
reply
Reply (2)
Latest replies

GLENMARK - 606929
GLENMARK reversal day results
300 to 346 and to 310 - 7 % down on our reversal day
@balrambull • Reputation: -1
GLENMARK

Type
Buy
Instrument
GLENMARK
Entry Price
₹329.45
Price@Trade
₹329.45
Target Price
₹340
Stop Price
₹326
Valid Till
Feb 12, 2020 3:20 PM
Margin
₹329.45 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹326
Net P&L
-1.05% Loss
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Feb 12 5:53 PM

Update
Stoploss Hit
Exit Price
₹326
@newsbot • Reputation: 2,308
Glenmark board to consider fund raising options on February 14
The Mumbai-based firm plans to raise funds either through issuance of bonds or debentures, non-convertible debt instruments or any other securities or any combination thereof, of any of the above, it added.
Moneycontrol
Like
reply
Reply
@rajivkumarjha • Reputation: -176,273
GLENMARK FEB20 330 CE

Type
Buy
Instrument
GLENMARK FEB20 330 CE
Entry Price
₹11.4
Price@Trade
₹11.4
Target Price
₹20
Stop Price
₹9.5
Valid Till
Feb 17, 2020 3:20 PM
Margin
₹15,960 approx for 1400 Qty
Status
Exited
Exit Price
₹13.5
Net P&L
18.42% Profit
Like
reply
Reply (1)
Latest replies
robotrade @rajivkumarjha
Feb 11 3:24 PM

Update
Exited
Exit Price
₹13.5
Net P&L
18.42% Profit
@tradingwiz • Reputation: 626
tradingwiz in GLENMARK

Wonderfully Hit all Targets... Enjoy friends
Like
reply
Reply
@nishantshah91 • Reputation: 3,415
GLENMARK

Type
Buy
Instrument
GLENMARK
Entry Price
₹324.5
Price@Trade
₹324.7
Target Price
₹350
Stop Price
₹312.9
Valid Till
Mar 6, 2020 3:20 PM
Margin
₹324.5 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹312.9
Net P&L
-3.57% Loss
T1 350 T2 360
Like
reply
Reply (5)
Latest replies
TrackerBot @trackerbot
Feb 7 3:25 PM

Update
Trade Entered
Entry Price
₹324.5
TradeAdda @nishantshah91
Feb 7 4:29 PM

326.50 from 324.50
TradeAdda @nishantshah91
Feb 7 4:38 PM

329.25 up almost 1.50% Intraday. Lot Size 1400.
TradeAdda @nishantshah91
Feb 11 9:09 PM

Made high 334.75 today from entry 324.50 lot size 1400 can keep Booking part as per comfort. #TradeAdda
TrackerBot @trackerbot
Feb 17 3:35 PM

Update
Stoploss Hit
Exit Price
₹312.9
@tradingwiz • Reputation: 626

GLENMARK - chart - 586980

Like
reply
Reply
@alokbihani • Reputation: 176

Amid the coronavirus Pharma industry is making new highs expect few.
Glenmark Pharma may see some resistance at 315.06, above that if sustained on 5min charts then can be considered for going long on the stock for short horizon. Target for that will be 319.55 followed by 324. At...
Read more...
Like
reply
Reply
@tradingwiz • Reputation: 626

GLENMARK - chart - 577765
levels on chart. kindly refer
1
reply
Reply
GLENMARK FEB20 FUT

Type
Sell
Instrument
GLENMARK FEB20 FUT
Entry Price
₹314.3
Price@Trade
₹314.3
Target Price
₹260
Stop Price
₹360
Valid Till
Feb 27, 2020 3:20 PM
Margin
₹81,999.41 approx for 1400 Qty
Status
Exited
Exit Price
₹308.75
Net P&L
9.48% Profit
Like
reply
Reply (1)
Latest replies

Update
Exited
Exit Price
₹308.75
Net P&L
9.48% Profit
@TTA • Reputation: 23,829
GLENMARK FEB20 FUT

Type
Buy
Instrument
GLENMARK FEB20 FUT
Entry Price
₹314.15
Price@Trade
₹314.15
Target Price
₹334
Stop Price
₹299
Valid Till
Feb 27, 2020 3:20 PM
Margin
₹82,250.57 approx for 1400 Qty
Status
Exited
Exit Price
₹315.4
Net P&L
2.13% Profit
Like
reply
Reply (1)
Latest replies
TTA @TTA
Feb 1 3:43 PM

Update
Exited
Exit Price
₹315.4
Net P&L
2.13% Profit
@newsbot • Reputation: 2,308
Low rollover seen ahead of Budget; Nifty rollovers at 66.30% for Feb series
Union Budget during the weekend might be a reason behind low rollover and fresh positions are likely to build post-event.
Moneycontrol
Like
reply
Reply
@sifm • Reputation: -4,176
GLENMARK JAN20 FUT

Type
Sell
Instrument
GLENMARK JAN20 FUT
Entry Price
₹326
Price@Trade
₹326
Target Price
₹320
Stop Price
₹330
Valid Till
Jan 30, 2020 3:20 PM
Margin
₹162,753.36 approx for 1400 Qty
Status
Exited
Exit Price
₹323.5
Net P&L
2.15% Profit
Like
reply
Reply (1)
Latest replies
Ashish Tiwari @sifm
Jan 30 5:44 PM

Update
Exited
Exit Price
₹323.5
Net P&L
2.15% Profit
@sifm • Reputation: -4,176
GLENMARK JAN20 FUT

Type
Sell
Instrument
GLENMARK JAN20 FUT
Entry Price
₹345
Price@Trade
₹345.35
Target Price
₹342
Stop Price
₹347
Valid Till
Jan 28, 2020 3:20 PM
Margin
₹86,383.79 approx for 1400 Qty
Status
Exited
Exit Price
₹345.35
Net P&L
-0.57% Loss
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Jan 28 7:53 PM

Update
Trade Entered
Entry Price
₹345
Ashish Tiwari @sifm
Jan 28 8:40 PM

Update
Exited
Exit Price
₹345.35
Net P&L
-0.57% Loss
GLENMARK JAN20 FUT

Type
Buy
Instrument
GLENMARK JAN20 FUT
Entry Price
₹352.4
Price@Trade
₹352.4
Target Price
₹416
Stop Price
₹340
Valid Till
Jan 30, 2020 3:20 PM
Margin
₹87,926.55 approx for 1400 Qty
Status
Stoploss Hit
Exit Price
₹340
Net P&L
-19.74% Loss
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Jan 29 3:53 PM

Update
Stoploss Hit
Exit Price
₹340
GLENMARK JAN20 FUT

Type
Buy
Instrument
GLENMARK JAN20 FUT
Entry Price
₹352.4
Price@Trade
₹352.4
Target Price
₹363
Stop Price
₹349
Valid Till
Jan 28, 2020 3:20 PM
Margin
₹87,926.55 approx for 1400 Qty
Status
Stoploss Hit
Exit Price
₹349
Net P&L
-5.41% Loss
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Jan 28 7:10 PM

Update
Stoploss Hit
Exit Price
₹349
@sagaani • Reputation: -16,172
SAGAANI in GLENMARK
GLENMARK
New trade: Buy GLENMARK, CMP@352, Enter@351.55 ...

safe traderswcan book profit and exit at 355others can alter stoploss
Like
reply
Reply
@sagaani • Reputation: -16,172
GLENMARK

Type
Buy
Instrument
GLENMARK
Entry Price
₹351.55
Price@Trade
₹352
Target Price
₹356
Stop Price
₹348  ₹352.55
Valid Till
Jan 27, 2020 3:20 PM
Margin
₹351.55 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹352.55
Net P&L
0.28% Profit
Like
reply
Reply (3)
Latest replies
TrackerBot @trackerbot
Jan 27 4:23 PM

Update
Trade Entered
Entry Price
₹351.55
SAGAANI @sagaani
Jan 27 6:20 PM

Update
Stoploss Trailed
Price @ Update
₹354.6
Original SL
₹348
New SL
₹352.55
TrackerBot @trackerbot
Jan 27 6:52 PM

Update
Stoploss Hit
Exit Price
₹352.55
@rajivkumarjha • Reputation: -176,273
GLENMARK JAN20 380 CE

Type
Buy
Instrument
GLENMARK JAN20 380 CE
Entry Price
₹2.2
Price@Trade
₹2.2
Target Price
₹15
Stop Price
₹1
Valid Till
Jan 30, 2020 3:20 PM
Margin
₹3,080 approx for 1400 Qty
Status
Stoploss Hit
Exit Price
₹1
Net P&L
-54.55% Loss
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Jan 27 2:49 PM

Update
Stoploss Hit
Exit Price
₹1
@kailashpatil • Reputation: -1,500
GLENMARK

Type
Sell
Instrument
GLENMARK
Entry Price
₹353
Price@Trade
₹353.55
Target Price
₹346
Stop Price
₹356
Valid Till
Jan 22, 2020 3:20 PM
Margin
₹353 approx for 1 Qty
Status
Exited
Exit Price
₹350
Net P&L
0.85% Profit
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Jan 22 4:42 PM

Update
Trade Entered
Entry Price
₹353
Kailash Patil @kailashpatil
Jan 22 8:19 PM

Update
Exited
Exit Price
₹350
Net P&L
0.85% Profit
@kailashpatil • Reputation: -1,500
GLENMARK

Type
Buy
Instrument
GLENMARK
Entry Price
₹361.5
Price@Trade
₹361.15
Target Price
₹371
Stop Price
₹355
Valid Till
Jan 20, 2020 3:20 PM
Margin
₹361.5 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹355
Net P&L
-1.8% Loss
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Jan 20 3:05 PM

Update
Trade Entered
Entry Price
₹361.5
TrackerBot @trackerbot
Jan 20 3:20 PM

Update
Stoploss Hit
Exit Price
₹355
@commodityBiz • Reputation: 17,316

GLENMARK - chart - 541800
SIGNAL TYPE - STRONG TIME FRAME- 1 HOURS
Like
reply
Reply (1)
Latest replies
Commodity Biz @commodityBiz
Jan 18 5:07 PM

👆👆👆👆👆👆👆👆Suggestion :- BUY IF PRICE COMES AGAIN AT 360 WITH SL OF 355 FOR TARGET OF 370
EXPECTATION OF TARGET- 1 DAYS
SIGNAL TYPE - STRONG TIME FRAME- 1 HOURS
@pyramidstock • Reputation: 2,460
Pyramidstock in GLENMARK
buy Glenmark pharam cmp 345-344 Sl 328 tgt 358-...

This is Also Running hows that?? from 345 to 364 more to come keep trailing sl and enjoy
Like
reply
Reply
@ronakm • Reputation: -6,409
GLENMARK

Type
Buy
Instrument
GLENMARK
Entry Price
₹355
Price@Trade
₹355.05
Target Price
₹400
Stop Price
₹335
Valid Till
Jan 15, 2021 3:20 PM
Margin
₹355 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹335
Net P&L
-5.63% Loss
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Jan 16 6:11 PM

Update
Trade Entered
Entry Price
₹355
TrackerBot @trackerbot
Jan 29 8:05 PM

Update
Stoploss Hit
Exit Price
₹335
@buffet • Reputation: 72
GLENMARK

Type
Buy
Instrument
GLENMARK
Entry Price
₹352
Price@Trade
₹352.35
Target Price
₹355
Stop Price
₹349
Valid Till
Jan 16, 2020 3:20 PM
Margin
₹352 approx for 1 Qty
Status
Target Achieved
Exit Price
₹355
Net P&L
0.85% Profit
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Jan 16 6:02 PM

Update
Trade Entered
Entry Price
₹352
TrackerBot @trackerbot
Jan 16 6:11 PM

Update
Target Achieved
Exit Price
₹355
@pyramidstock • Reputation: 2,460
Pyramidstock in GLENMARK
buy Glenmark pharam cmp 345-344 Sl 328 tgt 358-...

353 now more to come enjoy guys
Like
reply
Reply
@rajivkumarjha • Reputation: -176,273
GLENMARK JAN20 FUT

Type
Buy
Instrument
GLENMARK JAN20 FUT
Entry Price
₹348.4
Price@Trade
₹348.4
Target Price
₹368
Stop Price
₹339
Valid Till
Jan 30, 2020 3:20 PM
Margin
₹86,060.63 approx for 1400 Qty
Status
Exited
Exit Price
₹348.8
Net P&L
0.65% Profit
Like
reply
Reply (1)
Latest replies
robotrade @rajivkumarjha
Jan 16 5:04 PM

Update
Exited
Exit Price
₹348.8
Net P&L
0.65% Profit
@stocktrendr • Reputation: 319

Glenmark Pharma voluntary recall of multiple lots of Rantidine tablets in US
Like
reply
Reply
@pyramidstock • Reputation: 2,460

buy Glenmark pharam cmp 345-344 Sl 328 tgt 358-375-395
Like
reply
Reply
@thearyas • Reputation: -11,815
GLENMARK

Type
Sell
Instrument
GLENMARK
Entry Price
₹344
Price@Trade
₹343.9
Target Price
₹331
Stop Price
₹355
Valid Till
Jan 13, 2020 3:20 PM  Jan 15, 2020 3:20 PM
Margin
₹344 approx for 1 Qty
Status
Exited
Exit Price
₹339.65
Net P&L
1.26% Profit
Like
reply
Reply (3)
Latest replies
TrackerBot @trackerbot
Jan 13 3:43 PM

Update
Trade Entered
Entry Price
₹344
THE ARYAS @thearyas
Jan 13 8:44 PM

Update
Time Extended
Price @ Update
₹345.45
Original Time
Jan 13, 2020 3:20 PM
New Time
Jan 15, 2020 3:20 PM
THE ARYAS @thearyas
Jan 15 5:33 PM

Update
Exited
Exit Price
₹339.65
Net P&L
1.26% Profit
@Sharemarket • Reputation: -1,368

GLENMARK - 527826
Glenmark : Cmp 346.40
For Short Term Keep Buy Range 374-389 Target 410/420 Stop loss 360
Resistance 1 361
Resistance 2 374
Support 1 322
Support 2 305
Like
reply
Reply

💠💠
YOUR FREE EQUITY CASH CALL FOR THIS FORUM TODAY:
BUY GLENMARK AT THE VERY BEGINING
STRICT STOP LOSS - 335.75
1ST TARGET - 344
2ND TARGET - 346
3RD TARGET - 348
## GO WITH SAFER QUANTITY ##
Disclaimer: All my Views/Suggestions/Calls are for Education Purpose Only. Please con...
Read more...
1
reply
Reply
@invictotrader • Reputation: 2,665

Granules India, Glenmark Pharma rally 3% on drug approvals from USFDA Granules India got the nod for a painkiller, while Glenmark got it for Deferasirox tablets used in the treatment for chronic iron overload syndrome.
Like
reply
Reply
@stocktrendr • Reputation: 319

Glenmark Pharmaceuticals receives ANDA approval for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg
Like
reply
Reply
@100billionclub • Reputation: 3,727

Glenmark Pharmaceuticals Gets ANDA Approval For Deferasirox Tablets
Like
reply
Reply
@rajivkumarjha • Reputation: -176,273
GLENMARK JAN20 360 CE

Type
Buy
Instrument
GLENMARK JAN20 360 CE
Entry Price
₹8.95
Price@Trade
₹8.95
Target Price
₹15
Stop Price
₹3
Valid Till
Jan 13, 2020 3:20 PM
Margin
₹12,530 approx for 1400 Qty
Status
Exited
Net P&L
6.15% Profit
Like
reply
Reply (1)
Latest replies
robotrade @rajivkumarjha
Jan 9 7:03 PM

Update
Exited
Exit Price
₹9.5
Net P&L
6.15% Profit
GLENMARK JAN20 FUT

Type
Buy
Instrument
GLENMARK JAN20 FUT
Entry Price
₹358
Price@Trade
₹357
Target Price
₹380  ₹390
Stop Price
₹345
Valid Till
Jan 30, 2020 3:20 PM
Status
Exited before entry
Like
reply
Reply (2)
Latest replies

Update
Target Extended
Price @ Update
₹357.2
Original Target
₹380
New Target
₹390

Update
Exited before entry
Price @ Update
₹357.2
@100billionclub • Reputation: 3,727

TECH30: BUY GLENMARK ABV 350
Like
reply
Reply (1)
Latest replies
Billion Club @100billionclub
Dec 31 3:38 PM

*Harmonic, Tech30, Breakout and Carried calls mean High Accuracy Short term calls. Requested to All Client, Traders Or investors U must enter in this types of calls and get Huge profit*

GLENMARK - chart - 502858
Sell Glenmark at 345 for target 335-330 sl 352
1
reply
Reply

Glenmark
Buy Near 310 with SL of 294.9 for 325, 340
Sell Near 370 with SL of 385.1 for 355, 340
CMP 351 @ Dec 25
Like
reply
Reply
  • GLENMARK - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization14,876.17
    Enterprise Value17,679.79
    Price to Earnings14.67
    Price to Book Value1.43
    Return on Capital Employed0.11
    Return on Equity0.1
    Face Value1
    Dividend YieldNA
  • GLENMARK Share Price - Technicals

    keyboard_arrow_down
    GLENMARK - 52 Week High₹666.8
    GLENMARK - 52 Week Low₹267.25
  • GLENMARK - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    25-Nov-19Geojit Financial ServicesHold366
    25-Nov-19Geojit Financial ServicesHold366
    25-Nov-19Geojit Financial ServicesHold366
    3-Sep-19Geojit Financial ServicesSell338
    19-Aug-19HDFC SecuritiesBuy500
    GLENMARK Brokerage Price Target
  • GLENMARK Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Feb 20318.1325.95317.7321.55
    Feb 19313.3320313.3318.1
    Feb 18312.3314303.15311.95
    Feb 17342346.45305.4310.4
    Feb 14329.55337.3328333.8
  • GLENMARK Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹325
    30 Day Moving Average₹333.13
    50 Day Moving Average₹338.67
    100 Day Moving Average₹326.97
    200 Day Moving Average₹393.71
  • GLENMARK - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue6,4037,989.23-0.2
    Operating Profit1,3472,662.19-0.49
    Profit Before Tax1,2192,552.9-0.52
    Net Income1,0142,140.61-0.53
  • GLENMARK - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds10,3919,436.620.1
    Total Liabilities5,2694,790.480.1
    Total Assets15,66114,227.10.1
  • GLENMARK - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,124877.720.28
    Cash from Investing Activity-1,137-2,580.46-0.56
    Cash from Financing Activity-621,879.38-1.03
    Net Cash Flow-75176.64-1.42
  • GLENMARK - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.060.15
    Return on Equity0.10.23
    Return on Capital Employed0.110.22
  • GLENMARK - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.23
    3 Year CAGR Growth in Operating Profit0.04
    3 Year CAGR Growth in EBIDTA0.11
    3 Year CAGR Growth in Net Income0.01
    3 Yr CAGR Growth - Diluted EPS-0.03
  • GLENMARK - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue2.16
    5 Year CAGR Growth in Operating Profit3.05
    5 Year CAGR Growth in EBIDTA2.4
    5 Year CAGR Growth in Net Income1.63
    3 Yr CAGR Growth - Diluted EPS1.52
  • GLENMARK - Recent News

    keyboard_arrow_down
    NewsBot
    Feb 15 2:58 AM
    Glenmark Q3 net profit rises 64% to Rs 190.83 cr; to raise $400 mn
    Moneycontrol
    NewsBot
    Feb 14 10:43 PM
    Taking Stock | Supreme Court raps telcos for not paying up; Sensex falls below 50-DMA
    Moneycontrol
    NewsBot
    Feb 12 1:08 AM
    Glenmark board to consider fund raising options on February 14
    Moneycontrol
    NewsBot
    Jan 31 4:53 PM
    Low rollover seen ahead of Budget; Nifty rollovers at 66.30% for Feb series
    Moneycontrol
    NewsBot
    Oct 23 5:13 PM
    SBI Life, ICICI Pru, Siemens in MSCI India Index? Here's what Morgan Stanley thinks
    Moneycontrol
    NewsBot
    Oct 17 4:53 PM
    Glenmark Pharma gets USFDA nod for prostate cancer treatment drug
    Moneycontrol
    NewsBot
    Oct 14 9:48 PM
    Glenmark Q2 PAT may dip 46% YoY to Rs. 132.8 cr: Emkay
    Moneycontrol
    NewsBot
    Oct 9 3:48 PM
    Glenmark Pharma down 1% despite tentative USFDA nod for multiple sclerosis drug
    Moneycontrol
    NewsBot
    Oct 7 5:28 PM
    D-Street Buzz: Nifty Pharma falls 2%; Glenmark, Auro Pharma, Piramal Enterprises, Lupin touch 52-week lows
    Moneycontrol
    NewsBot
    Oct 7 3:23 PM
    Glenmark Pharma hits 52-week low on USFDA warning letter for Baddi facility
    Moneycontrol
  • GLENMARK - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Cipla Ltd. Sector: Pharmaceuticals a...
    Dr. Reddy's Laboratories Ltd. Sector...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Piramal Enterprises Ltd. Sector: Phar...
    Divi's Laboratories Ltd. Sector: Pha...
    Strides Pharma Science Ltd. Sector: P...
    Apollo Hospitals Enterprise Ltd. Sec...
  • GLENMARK - More Information

    keyboard_arrow_down

    Glenmark Pharmaceuticals Ltd:
    Glenmark Pharmaceuticals, a company that deals with pharmaceutical products, was established in 1977 by Gracias Saldanha which headquarter is in Mumbai, India. It manufactures generic drugs and various active pharmaceutical ingredients.
    The company was named after the name of his two sons, Glenn and Mark. In the beginning, the company used to sell the products in India, Africa, and Russia. The company came to the public in the year 1999, and also took some procedures and built its research facility for the first time. Glenmark Saldanha’s elder son Glenn had the invasion as the CEO of the company in 2001 after working at PricewaterhouseCoopers when he came back to India.
    In 2008, Glenmark became the fifth-biggest company for pharmaceuticals in India. Glenmark entered into the market of dermatology by launching ‘Candid Cream’. Dermatology is one of the key focus areas of Glenmark, until today.
    About Company Information:
    The company entered the market of dermatology by launching Candid Cream in 1979, at the very beginning. In 1980, the company began to export their products outside of the country. In 1983, it incorporated its manufacturing facility for the very first time at Nasik, Maharashtra.
    The R&D department was founded in the plant at Nasik in 1984. The company introduced Ascoril in the market in 1987. The company initiated operating its business in Srilanka, Afghanistan, Mauritius, and Kenya in 1989. It expanded the plant at Nasik in 1992. It integrated a wholly possessed subordinate company, Glenmark Exports Pvt Ltd to strengthen its position internationally in the market of pharmaceuticals in 1996.
    In Brazil, the company started to sell pharmaceutical products in 1999. The company entered into the segment of diabetes in 2000. The company initiated the business of manufacturing API in 2001. It obtained a facility of API manufacturing from Glaxosmithkline Pharmaceuticals at Ankleshwar, Gujarat in 2002. Glenmark has done its out-licensing deal for the first time to discover R&D in 2004.
    The company commissioned a new facility for manufacture at Baddi, Himachal Pradesh in 2005. It signed an out-licensing contract with Merk KGaA, Germany in 2006, for Melogliptin. The company received the approval of MHRA, the UK for their plant at Baddi in 2007.
    The company re-organized its business and integrated a company namely Glenmark Generics as its subordinate one in 2008. During 2009-10, it integrated Glenmark Generics B.V. in the Netherlands. Glenmark signed the Development Agreement with Forest Laboratories to collaborate on Novel Agents.
    The company made the announcement of launching a cream namely Hydrocortisone Butyrate in the US, in 2013. Glenmark brought together its two subsidiary companies which are Glenmark Generics Ltd. and Glenmark Access Ltd. with GPL in the year 2014. The company disclosed its approval and launching of Verapamil and Trandolapril Hydrochloride in 2015.
    Glenmark announced the strategic blueprint of its evolution to an innovation-led globally spread pharmaceutical organization on 19th December 2016. The blueprint bears its greater alignment of business spreading generics to give priority mostly to the research and development efforts in three core therapeutic sections: respiratory, oncology and dermatology.
    The company announced affirmative results for GSP 301 on 30th March 2017. The company has also announced that it has submitted an NDA to the FDA of US for Ryaltris, the respiratory pipeline candidate, which is basically a tentative fixed-dose nasal spray which is a combination of a steroid and an antihistamine that is used for treatment of seasonal allergic rhinitis (SAR) and it was announced on 22nd May 2018.
    The company announced on 19th June 2018 that the first supplemental Abbreviated New Drug Application (SANDA) was provided by the US Food and Drug Administration for the manufacturing facility of the company in Monroe, New Carolina. The Monroe facility in New Carolina is the first manufacturing plant of Glenmark in the US which is founded to manufacture various pharmaceutical products of fixed does. The company has made an investment of more than $100 million on that facility along with some planning of further development in upcoming years.
    How Glenmark Pharmaceuticals Ltd is categorised as Pharmaceuticals and Health Care Sector and Pharmaceuticals Industry.
    Pharmaceuticals and Health care sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more. The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Glenmark Pharmaceuticals Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Glenmark Pharmaceuticals Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.